Relapse Prevention with Tyrosine Kinase Inhibitors after Allogeneic Transplantation for Philadelphia Chromosome–Positive Acute Lymphoblast Leukemia: A Systematic Review

医学 达沙替尼 内科学 伊马替尼 尼罗替尼 肿瘤科 移植 费城染色体 造血干细胞移植 回顾性队列研究 甲磺酸伊马替尼 髓系白血病 染色体易位 基因 生物化学 化学
作者
Zabih Warraich,Pavan Tenneti,Theresa Thai,Anne Hubben,Hina Amin,Ali McBride,Sami Ullah Warraich,Abdul Hannan,Faiza Hassan Warraich,Navneet S. Majhail,Matt Kalaycio,Faiz Anwer
出处
期刊:Biology of Blood and Marrow Transplantation [Elsevier BV]
卷期号:26 (3): e55-e64 被引量:53
标识
DOI:10.1016/j.bbmt.2019.09.022
摘要

Abstract

Relapse after stem cell transplantation for Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL) remains a significant challenge. In this systematic review, we compare survival outcomes of second-generation tyrosine kinase inhibitors (TKIs) nilotinib and dasatinib with first-generation TKI imatinib when these agents are used after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in Ph+ ALL. In addition, we review the literature on TKI use to prevent relapse in patients who proceed to allo-HSCT beyond first complete response (>CR1). We performed database searches (inception to January 2018) using PubMed, Cochrane Library, and Embase. After exclusions, 17 articles were included in this analysis. Imatinib was used post-transplant either prophylactically or preemptively in 12 studies, 7 prospective studies and 5 retrospective studies. Overall survival (OS) for most prospective studies at 1.5 to 3 and 5 years ranged between 62% to 92% and 74.5% to 86.7%. Disease-free survival at 1.5 to 5 years was 60.4% to 92%. Additionally, imatinib failed to show survival benefit in patients who were >CR1 at the time of allo-HSCT. The cumulative OS for most retrospective studies using imatinib at 1 to 2 and 3 to 5 years was 42% to 100% and 33% to 40% respectively. Event-free survival at 1 to 2 and 3 to 5 years was 33.3% to 67% and 20% to 31% respectively. Dasatinib was used as maintenance treatment in 3 retrospective studies (n = 34). The OS for patients with Ph+ ALL using dasatinib as maintenance regimen after allo-HSCT at 1.4 to 3 years was 87% to 100% and disease-free survival at 1.4 to 3 years was 89% to 100%. Ninety-three percent of patients with minimal residual disease (MRD) positive status after allo-HSCT became MRD negative. Three prospective studies used nilotinib. In 2 studies where investigators studied patients with advanced chronic myeloid leukemia and Ph+ ALL, the cumulative OS and event-free survival at 7.5 months to 2 years were 69% to 84% and 56% to 84%, respectively. In the third study (n = 5) in patients with Ph+ ALL, nilotinib use resulted in OS at 5 years of 60%. Our review showed that use of TKIs (all generations) after allo-HSCT for patients in CR1 improved OS when given as a prophylactic or preemptive regimen. Limited data suggest that second-generation TKIs (ie, dasatinib) have a better OS, especially in patients with MRD-positive status. Imatinib did not improve OS in patients who were >CR1 at the time of allo-HSCT; for this population, no data were available with newer generation TKIs. The evaluation of survival benefit with newer generation TKIs and their efficacy in patients in >CR1 needs further study in large randomized clinical trials.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
sdl发布了新的文献求助10
刚刚
emmm完成签到 ,获得积分10
1秒前
十三发布了新的文献求助10
1秒前
2秒前
2秒前
liangmh完成签到,获得积分10
2秒前
一二不休完成签到,获得积分10
2秒前
123发布了新的文献求助10
3秒前
5秒前
ding应助黑熊安巴尼采纳,获得10
6秒前
Ava应助wjxcl采纳,获得10
6秒前
闪闪如南发布了新的文献求助10
6秒前
深情安青应助一二不休采纳,获得10
7秒前
9秒前
123完成签到,获得积分10
9秒前
不扯先生完成签到,获得积分10
10秒前
柳絮完成签到,获得积分20
11秒前
lll完成签到,获得积分10
11秒前
sdl完成签到,获得积分10
11秒前
Orange应助孟婆的碗采纳,获得10
12秒前
zhangmy1989发布了新的文献求助30
12秒前
12秒前
清秀的不言完成签到 ,获得积分10
12秒前
杂化轨道退役研究员完成签到,获得积分10
12秒前
FashionBoy应助tanglu采纳,获得10
13秒前
14秒前
闪闪如南完成签到,获得积分10
15秒前
wjxcl完成签到,获得积分10
16秒前
16秒前
16秒前
12233完成签到,获得积分10
17秒前
17秒前
洪武完成签到,获得积分20
17秒前
18秒前
Yuantian发布了新的文献求助10
19秒前
传奇3应助浪花淘尽英雄采纳,获得10
20秒前
流川枫完成签到,获得积分10
20秒前
赘婿应助leo采纳,获得10
20秒前
追寻夏烟完成签到 ,获得积分10
21秒前
闪闪寒云完成签到 ,获得积分10
21秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038569
求助须知:如何正确求助?哪些是违规求助? 3576279
关于积分的说明 11374944
捐赠科研通 3305979
什么是DOI,文献DOI怎么找? 1819354
邀请新用户注册赠送积分活动 892698
科研通“疑难数据库(出版商)”最低求助积分说明 815048